Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - American Depositary Shares
(NQ:
ASND
)
233.63
+4.64 (+2.03%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma A/S - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months
↗
June 14, 2021
The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
↗
June 01, 2021
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...
Via
Benzinga
What 5 Analyst Ratings Have To Say About Ascendis Pharma
↗
June 01, 2021
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1...
Via
Benzinga
Earnings Scheduled For June 1, 2021
↗
June 01, 2021
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is expected to report quarterly loss at $0.11 per share on revenue of $10.82 million. • Canopy...
Via
Benzinga
Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript
↗
May 28, 2021
ASND earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
↗
May 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...
Via
Benzinga
The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation
↗
May 23, 2021
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts....
Via
Benzinga
Earnings Scheduled For May 27, 2021
↗
May 27, 2021
Companies Reporting Before The Bell • Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.48 per share on revenue of $11.77 billion. •...
Via
Benzinga
Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism
↗
May 11, 2021
Ascendis Pharma A/S (NASDAQ: ASND) has announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the Phase 2 PaTH...
Via
Benzinga
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
↗
May 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...
Via
Benzinga
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
↗
April 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
April 19, 2021
During Monday's morning trading, 29 companies set new 52-week lows. Intriguing Points: Ascendis Pharma (NASDAQ:ASND) is the largest company in terms of market...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.